LEADER 01121nam0-2200361---450 001 990008824580403321 005 20210722162639.0 035 $a000882458 035 $aFED01000882458 035 $a(Aleph)000882458FED01 100 $a20090316d1983----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $aDal simbolo al mito$fAlfred Baemler, Friedrich Creuzer, Johann J. Bachofen$ga cura di Giampiero Moretti$gpresentazione di Carlo Sini 210 $aMilano$cSpirali$dc1983 215 $a190 p.$d21 cm 225 1 $aCome pensare 700 1$aBaeumler,$bAlfred$0152562 701 1$aCreuzer,$bFriedrich$0152809 701 1$aBachofen,$bJohann Jakob$f<1815-1887>$0143791 702 1$aMoretti,$bGiampiero$f<1955- > 702 1$aSini,$bCarlo 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990008824580403321 952 $a458 SEZ. ANDRIELLO$b458$fDARPU 952 $aDFT A 06 A 03(1$b2021/602$fFLPBC 952 $aDFT A 06 A 03(2$b2021/603$fFLPBC 959 $aDARPU 959 $aFLFBC 996 $aDal simbolo al mito$995479 997 $aUNINA LEADER 03531nam 22006015 450 001 9910483946703321 005 20260216132100.0 010 $a3-030-72676-2 010 $a3030726754 010 $z9783030726768 010 $a3030726754 010 $z9783030726751 024 7 $a10.1007/978-3-030-72676-8 035 $a(CKB)4100000011930277 035 $a(DE-He213)978-3-030-72676-8 035 $a(MiAaPQ)EBC6627527 035 $a(Au-PeEL)EBL6627527 035 $a(OCoLC)1252424381 035 $a(PPN)25588219X 035 $a(EXLCZ)994100000011930277 100 $a20210518d2021 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAcute Myeloid Leukemia /$fedited by Christoph Röllig, Gert J. Ossenkoppele 205 $a1st ed. 2021. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2021. 215 $a1 online resource (viii, 358 pages) $cillustrations 225 1 $aHematologic Malignancies,$x2197-9774 311 08$a3-030-72675-4 320 $aIncludes bibliographical references. 327 $a1. Epidemiology and Etiology -- 2. Diagnosis and Classification of AML: WHO 2016 -- 3. The Genomic Landscape and Clonal Evolution of AML -- 4. Clinical Manifestation and Diagnostic Workup -- 5. Prognostic Factors and Treatment Allocation -- 6. Treatment of Acute Promyelocytic Leukemia -- 7. Treatment of Newly Diagnosed AML in FitPatients -- 8. Treatment of Newly Diagnosed AML in Unfit Patients -- 9. Treatment of Relapsed and Refractory AML -- 10. Allogeneic Stem Cell Transplantation -- 11. Special Clinical Scenarios -- 12. Future Developments. 330 $aThis book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults. The opening chapters present current knowledge of epidemiology, etiologic factors, and the pathogenesis and molecular development of AML. Detailed guidance is offered on laboratory and clinical diagnostic workup and disease classification, and the patient- and disease-related factors that determine prognosis and treatment allocation are identified. On the basis of these general considerations, initial treatments in patients considered fit for intensive treatment and in older and co-morbid patients are reviewed, and the available relapse treatment strategies, explained. For all clinical scenarios, the most recent data on the optimal use of newly approved agents in different AML subgroups are presented. Separate chapters address the treatment of acute promyelocytic leukemia, current practice of allogeneic stem cell transplantation, and special clinical situations. Finally, promising approaches in drug development, current standards and challenges in assessment of measurable residual disease, immune approaches, and ideas for innovative trial designs are considered. 410 0$aHematologic Malignancies,$x2197-9774 606 $aHematology 606 $aHematology 606 $aLeucèmia mieloide$2thub 608 $aLlibres electrònics$2thub 615 0$aHematology. 615 14$aHematology. 615 7$aLeucèmia mieloide 676 $a616.99419 702 $aRo?llig$b Christoph 702 $aOssenkoppele$b Gert J. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910483946703321 996 $aAcute Myeloid Leukemia$92005821 997 $aUNINA